A resorcylic acid lactone, L-783,277, isolated from a Phoma sp. (ATCC 74403) which came from the fruitbody of Helvella acetabulum, is a potent and specific inhibitor of MEK (Map kinase kinase). L-783,277 inhibits MEKwith an IC50 value of 4nM. It weakly inhibits Lck and is inactive against Raf, PKAand PKC. L-783,277 is an irreversible inhibitor of MEK and is competitive with respect to ATP. L-783,290, the tmns-isomQv of L-783,277, was isolated from the same culture and evaluated together with several semi-synthetic resorcylic acid lactone analogs. A preliminary structure-activity relationship is presented. Several independent cellbased assays have been carried out to study the biological activities of these resorcylic acid lactone compoundsand a brief result summaryfrom these studies is presented.
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MEKnis a threonine/tyrosine specific kinase involved in the MAPkinase cascade that begins with the stimulation of the proto-oncoprotein Ras in response to a wide variety of extracellular stimuli such as nerve growth factor, insulin, platelet derived-growth factor and expression of some oncogenes1 2). Located directly upstream of MEK, the raf kinases are activated by Ras4) and MEKis then phosphorylated and activated by Raf3). MEKconsists of two dual specificity protein kinase isoforms, MEK1 and MEK21314). The activation of MEK1by å Raf involves the phosphorylation of two serine residues within the catalytic domain15 Fermentation extracts or purified compoundswere diluted in 50% aqueous DMSO.The final DMSOconcentrations were 2.5% for both assays. Reactions were run at room temperature and terminated with an equal volume of 100mM EDTA, lOOmM sodium pyrophosphate. Phosphorylated product was captured in 96-well Immobilon-P filter plates (Millipore). Filters were washed 5 times with H2Oand counted on a TopCountmicroplate scintillation counter in the presence of Microscint (Packard).
The same protocol was followed as described above whendifferent concentrations of ATPwere used.
Lck Protein Kinase Assay
The Lck protein kinase assay using the SPA technique was performed as described20' 21)24).
Protein Kinase C (PKC) Assay
The procedures for the PKCassay are modified from those developed by Gopalakrishna et al22) Fermentation extracts or purified compounds (5jal) in 50% aqueous DMSOwere mixed with 0.06nM PKC, Ajim MBPas substrate, IO^m ATP and 0.7^Ci of [>33P]ATP in final volume of 100/il containing 20mM Tris pH 7.5, 10mM MgCl2, 0.25mM EGTA, 0.4mM CaCl2, lOO^g/ml BSA, 0.32 mg/ml phosphatidylserine, 0.032 mg/ml diacylglycerol and 1 mM/3-mercaptoethanol. The mixtures were incubated for 20 minutes at roomtemperature and filter plates were processed as described above.
Protein Kinase A (PKA) Assay
The procedures for the PKAassay are modified from those developed by Pitt and Lee23 MEKkinase assays were performed in the presence of L-783,277 at the indicated concentrations. After 2 hours at room temperature, the assays were stopped and processed as described in the Methods section. The data shown are the means± SD(n= 3) from a single experiment and are representative of three separate experiments.
Raf, Lck, and activated H-Ras at multiplicity of infection of 10:2:2:2. The cells were lysed by sonication in 20mM Tris pH 7.5, 150him NaCl, 1mM Na3VO4, 50mM NaF, lniM EDTA, lmM MgCl2, 1% Triton X-100, protease inhibitor cocktail (10 /ig/ml benzamidine, 5 /xg/ml each of Hyp othemyc in 300 15 >13000 >13000 >13000 750 >55000 >50000 >50000 45000 >88000 >52000 >88000 2800
Each compoundwas titrated in triplicate in the indicated kinase assays. The average percent inhibitions were calculated and the IC50 of each compound was determined by a semi-log plot of the percent inhibition of the compoundversus the concentration of compoundtested. Table 2 ) and weakly inhibits Lck (IC50=750nM, a 188-fold difference, Table 2 ). L-783,277 does not inhibit Raf, PKC and PKA activities ( Table 2 ), suggesting that L-783,277 is a potent and specific inhibitor of MEK.L-783,290 is a weaker inhibitor of MEKactivity (IC50=300 nM, Table 2 ) and does not inhibit other kinases. Hypothemycin is 2-3 fold less active than L-783,277 against MEK(IC50= 15 nM) and is a weaker inhibitor ofLck (IC50=2800nM, a 187-fold difference, Table 2 IC50 values (in nM) were obtained as described in Table 1 . Reduction of the a, [5 unsaturated ketone of L-783,277 dramatically decreased the potency of this compound (see text for details).
The a, f5 Unsaturated Ketone ofL-783,277 is Critical for MEKInhibitory Activity To examine whether the a, ji unsaturated ketone of L-783,277 was essential for activity, this moiety was reduced with NaBH4. The expected two isomers were weaker inhibitors of MEKwith IC50 values of 1,600 and 20,000 nM (Table 3 783,277 and related resorcylic acid lactones will facilitate further study of the mechanism of activation/inhibition of the MAP kinase pathway and could lead to the identification of therapeutically useful anti-cancer agents.
